IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS infectious diseases 2020 imex curation Freitas BT., Durie IA., Murray J., Longo JE., Miller HC., Crich D., Hogan RJ., Tripp RA., Pegan SD. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus The catalytic core of SARS-CoV-2 PLpro (orf1ab 1564-1876) is stated to be 315 aa in methods, but aas 1564-1876 is only 313 residues. spegan@uga.edu,scott.d.pegan.mil@mail.mil 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation in vitro In vitro cleavage cleavage assay cleavage predetermined predetermined participant predetermined Freitas BT., Durie IA., Murray J., Longo JE., Miller HC., Crich D., Hogan RJ., Tripp RA., Pegan SD. Virus - Publications including interactions involving viral proteins The catalytic core of SARS-CoV-2 PLpro (orf1ab 1564-1876) is stated to be 315 aa in methods, but aas 1564-1876 is only 313 residues. please check the KCat/Km values entered- :- Kcat /60 to get per sec value, then /1000 to convert to "M" rather than "uM". I have only added inhibitors with low IC50 values. The increase in AMC fluorescence was observed after the cleavage of AMC from Ub-AMC and ISG15-AMC. spegan@uga.edu,scott.d.pegan.mil@mail.mil Accepted 2021-JAN-26 AT 17:01 GMT AT 17:01 GMT by KALPANAP ACS infectious diseases 2020 Only protein-protein interactions imex curation imex curation Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS infectious diseases 2020 imex curation Freitas BT., Durie IA., Murray J., Longo JE., Miller HC., Crich D., Hogan RJ., Tripp RA., Pegan SD. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus The catalytic core of SARS-CoV-2 PLpro (orf1ab 1564-1876) is stated to be 315 aa in methods, but aas 1564-1876 is only 313 residues. spegan@uga.edu,scott.d.pegan.mil@mail.mil 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation in vitro In vitro deubiquitinase assay deubiquitinase assay deubiquitinase assay weight by comassie molecular weight estimation by coomasie staining weight by comassie Freitas BT., Durie IA., Murray J., Longo JE., Miller HC., Crich D., Hogan RJ., Tripp RA., Pegan SD. Virus - Publications including interactions involving viral proteins The catalytic core of SARS-CoV-2 PLpro (orf1ab 1564-1876) is stated to be 315 aa in methods, but aas 1564-1876 is only 313 residues. spegan@uga.edu,scott.d.pegan.mil@mail.mil Accepted 2021-JAN-26 AT 17:01 GMT AT 17:01 GMT by KALPANAP ACS infectious diseases 2020 Only protein-protein interactions imex curation imex curation Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS infectious diseases 2020 imex curation Freitas BT., Durie IA., Murray J., Longo JE., Miller HC., Crich D., Hogan RJ., Tripp RA., Pegan SD. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus The catalytic core of SARS-CoV-2 PLpro (orf1ab 1564-1876) is stated to be 315 aa in methods, but aas 1564-1876 is only 313 residues. spegan@uga.edu,scott.d.pegan.mil@mail.mil 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation in vitro In vitro protease assay protease assay weight identificat confirmation by molecular weight weight identificat Freitas BT., Durie IA., Murray J., Longo JE., Miller HC., Crich D., Hogan RJ., Tripp RA., Pegan SD. Virus - Publications including interactions involving viral proteins The catalytic core of SARS-CoV-2 PLpro (orf1ab 1564-1876) is stated to be 315 aa in methods, but aas 1564-1876 is only 313 residues. I cannot find any expression system for the ISG15 proteins used here. Trihalo compounds in Mini-PROTEAN TGX Stain-Free Gels react with tryptophan residues in proteins in a UV-induced 1-minute reaction to produce fluorescence. spegan@uga.edu,scott.d.pegan.mil@mail.mil Accepted 2021-JAN-26 AT 17:01 GMT AT 17:01 GMT by KALPANAP ACS infectious diseases 2020 Only protein-protein interactions imex curation imex curation r9qb93_tupbe protein protein Common tree shrew Tupaia belangeri Tupaia glis belangeri MGRDLKVKMLGGQEFMVPISDSMLAMELKQKITKKIGVPAFQQRLAIHPSGTVLQDRVPLGHQGLDSDSIVLLVVQSCDSPLNILVRNNKGRSSSYEVRLTQTVAHLKQLVSQQEGVQADLFWLSYEGRDMEDQKPLGEYGLMSQSTVYMHLRLRGG 0B726FC5E061ED29 b2lug8_pig protein protein pig Sus scrofa (Pig) Pig MGRELKVKMLGGKEILVPLRDCMMASDLKQQIAREIGVPAFQQRLAHPAGNVLQDGVPLVNQGLGPGSMVLLMVQSFRDPLSILVRNDKGRSNAYEVWLTQTVAELKQQVCQLEGVQADHFWLTFEGKPMEDEHQLGEYDLKPMCTVYMNLRLRGGGTGPGEHLTEC 96CF6AA3214A5014 p0dtd1-pro_0000449621 Papain-like protease nsp3 rep ORF1ab polyprotein 1a-1b protein protein SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 2019-nCoV APTKVTFGDDTVIEVQGYKSVNITFELDERIDKVLNEKCSAYTVELGTEVNEFACVVADAVIKTLQPVSELLTPLGIDLDEWSMATYYLFDESGEFKLASHMYCSFYPPDEDEEEGDCEEEEFEPSTQYEYGTEDDYQGKPLEFGATSAALQPEEEQEEDWLDDDSQQTVGQQDGSEDNQTTTIQTIVEVQPQLEMELTPVVQTIEVNSFSGYLKLTDNVYIKNADIVEEAKKVKPTVVVNAANVYLKHGGGVAGALNKATNNAMQVESDDYIATNGPLKVGGSCVLSGHNLAKHCLHVVGPNVNKGEDIQLLKSAYENFNQHEVLLAPLLSAGIFGADPIHSLRVCVDTVRTNVYLAVFDKNLYDKLVSSFLEMKSEKQVEQKIAEIPKEEVKPFITESKPSVEQRKQDDKKIKACVEEVTTTLEETKFLTENLLLYIDINGNLHPDSATLVSDIDITFLKKDAPYIVGDVVQEGVLTAVVIPTKKAGGTTEMLAKALRKVPTDNYITTYPGQGLNGYTVEEAKTVLKKCKSAFYILPSIISNEKQEILGTVSWNLREMLAHAEETRKLMPVCVETKAIVSTIQRKYKGIKIQEGVVDYGARFYFYTSKTTVASLINTLNDLNETLVTMPLGYVTHGLNLEEAARYMRSLKVPATVSVSSPDAVTAYNGYLTSSSKTPEEHFIETISLAGSYKDWSYSGQSTQLGIEFLKRGDKSVYYTSNPTTFHLDGEVITFDNLKTLLSLREVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDPSFLGRYMSALNHTKKWKYPQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCNKTVGELGDVRETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMYMGTLSYEQFKKGVQIPCTCGKQATKYLVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQCGHYKHITSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIKPVTYKLDGVVCTEIDPKLDNYYKKDNSYFTEQPIDLVPNQPYPNASFDNFKFVCDNIKFADDLNQLTGYKKPASRELKVTFFPDLNGDVVAIDYKHYTPSFKKGAKLLHKPIVWHVNNATNKATYKPNTWCIRCLWSTKPVETSNSFDVLKSEDAQGMDNLACEDLKPVSEEVVENPTIQKDVLECNVKTTEVVGDIILKPANNSLKITEEVGHTDLMAAYVDNSSLTIKKPNELSRVLGLKTLATHGLAAVNSVPWDTIANYAKPFLNKVVSTTTNIVTRCLNRVCTNYMPYFFTLLLQLCTFTRSTNSRIKASMPTTIAKNTVKSVGKFCLEASFNYLKSPNFSKLINIIIWFLLLSVCLGSLIYSTAALGVLMSNLGMPSYCTGYREGYLNSTNVTIATYCTGSIPCSVCLSGLDSLDTYPSLETIQITISSFKWDLTAFGLVAEWFLAYILFTRFFYVLGLAAIMQLFFSYFAVHFISNSWLMWLIINLVQMAPISAMVRMYIFFASFYYVWKSYVHVVDGCNSSTCMMCYKRNRATRVECTTIVNGVRRSFYVYANGGKGFCKLHNWNCVNCDTFCAGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVTVKNGSIHLYFDKAGQKTYERHSLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCEESSAKSASVYYSQLMCQPILLLDQALVSDVGDSAEVAVKMFDAYVNTFSSTFNVPMEKLKTLVATAEAELAKNVSLDNVLSTFISAARQGFVDSDVETKDVVECLKLSHQSDIEVTGDSCNNYMLTYNKVENMTPRDLGACIDCSARHINAQVAKSHNIALIWNVKDFMSLSEQLRKQIRSAAKKNNLPFKLTCATTRQVVNVVTTKIALKGG 819 2763 q6tfz7_9viru Replicase Transcriptase protein protein Crimean-Congo hemorrhagic fever orthonairovirus Crimean-Congo hemorrhagic fever orthonairovirus MDFLRSLDWTQVIAGQYVSNPRFNISDYFEIVRQPGDGNCFYHSIAELTMPNKTDHSYHYIKRLTESAARKYYQEEPEARLVGLSLEDYLKRMLSDNEWGSTLEASMLAKEMGITIIIWTVAASDEVEAGIKFGDGDVFTAVNLLHSGQTHFDALRILPQFETDTREALSLMDRVIAVDQLTSSSSDELQDYEDLALALTSAEESNRRSSLDEVTLSKKQAEILRQKASQLSKLVNKSQNIPTRVGRVLDCMFNCKLCVEISADTLILRPESKEKIGEIMSLRQLGHKLLTRDKQIKQEFSRMKLYVTKDLLDHLDVGGLLRAAFPGTGIERHMQLLHSEMILDICTVSLGVMLSTFLYGSNNKNKKKFITNCLLSTALSGKKVYKVLGNLGNELLYKAPRKALATVCSALFGKQINKLQNCFRTISPVSLLALRNLDFDCLSVQDYNGMIENMSKLDNTDVEFNHREIADLNQLTSRLITLRKEKDTDLLKQWFPESDLTRRSIRNAANAEEFVISEFFKKKDIMKFISTSGRAMSAGKIGNVLSYAHNLYLSKSSLNMTSEDISQLLIEIKRLYALQEDSEVEPIAIICDGIESNMKQLFAILPPDCARECEVLFDDIRNSPTHSTAWKHALRLKGTAYEGLFANCYGWQYIPEDIKPSLTMLIQTLFPDKFEDFLDRTQLHPEFRDLTPDFSLTQKVHFKRNQIPSVENVQISIDATLPESVEAVPVTERKMFPLPETPLSEVHSIERIMENFTRLMHGGRLSTKKRDGDPAEQGNQQSITEHESSSISAFKDYGERGIVEENHMKFSGEDQLETRQLLLVEVGFQTDIDGKIRTDHKKWKDILKLLELLGIKCSFIACADCSSTPPDRWWITEDRVRVLKNSVSFLFNKLSRNSPTEVTDIVVGAISTQKVRSYLKAGTATKTPVSTKDVLETWEKMKEHILNRPTGLTLPTSLEQAMRKGLVEGVVISKEGSESCINMLKENLDRITDEFERTKFKHELTQNITTSEKMLLSWLSEDIKSSRCGECLSNIKKAVDETANLSEKIELLAYNLQLTNHCSNCHPNGVNISNTSNVCKRCPKIEVVSHCENKGFEDSNECLTDLDRLVRLTLPGKTEKERRVKRNVEYLIKLMMSMSGIDCIKYPTGQLITHGRVSAKHNDGNLKDRSDDDQRLAEKIDTVRKELSESKLKDYSTYARGVISNSLKNLSRQGKSKCSVPRSWLEKVLFDLKVPTKDEEVLINIRNSLKARSEFVRNNDKLLIRSKEELKKCFDVQSFKLKKNKQPVPFQVDCILFKEVAAECMKRYIGTPYEGIVDTLVSLINVLTRFTWFQEVVLYGKICETFLRCCTEFNRSGVKLVKIRHCNINLSVKLPSNKKENMLCCLYSGNMELLQGPFYLNRRQAVLGSSYLYIVITLYIQVLQQYRCLEVINSVSEKTLQDIENHSMTLLEDSFREITFALEGRFEESYKIRTSRCRASGNFLNRSSRDHFISVVSGLNLVYGFLIKDNLLANSQQQNKQLQMLRFGMLAGLSRLVCPNELGKKFSTSCRRIEDNIARLYLQTSIYCSVRDVEDNVKHWKQRDLCPEVTIPCFTVYGTFVNSDRQLIFDIYNVHIYNKEMDNFDEGCISVLEETAERHMLWELDLMNSLCSDEKKDTRTARLLLGCPNVRKAANREGKKLLKLNSDTSTDTQSIASEVSDRRSYSSSKSRIRSIFGRYNSQKKPFELRSGLEVFNDPFNDYQQAITDICQFSEYTPNKESILKDCLQIIRKNPSHTMGSFELIQAISEFGMSKFPPENIDKARRDPKNWVSISEVTETTSIVASPRTHMMLKDCFKIILGTENKKIVKMLRGKLKKLGAISTNIEIGKRDCLDLLSTVDGLTDQQKENIVNGIFEPSKLSFYHWKELVKKNIDEVLLTEDGNLIFCWLKTISSSVKGSLKKRLKFMNIHSPELMPENCLFSSEEFNELIKLKKLLLNEQQDEQELKQDLLISSWIKCITACKDFASINDKIQKFIYHLSEELYDIRLQHLELSKLKQEHPSVSFTKEEVLIKRLEKNFLKQHNLEIMETVNLVFFAALSAPWCLHYKALESYLVRHPEILDCGSKEDCKLTLLDLSVSKLLVCLYQKDDEELINSSSLKLGFLVKYVVTLFTSNGEPFSLSLNDGGLDLDLHKTTDEKLLHQTKIVFAKIGLSGNSYDFIWTTQMIANSNFNVCKRLTGRSTGERLPRSVRSKVIYEMVKLVGETGMAILQQLAFAQALNYEHRFYAVLAPKAQLGGARDLLVQETGTKVMHATTEMFSRNLLKTTSDDGLTNPHLKETILNVGLDCLANMRNLDGKPISEGSNLVNFYKVICISGDNTKWGPIHCCSFFSGMMQQVLKNVPDWCSFYKLTFIKNLCRQVEIPAGSIKKILNVLRYRLCSKGGVEQHSEEDLRRLLTDNLDSWDGNDTVKFLVTTYISKGLMALNSYNHMGQGIHHATSSVLTSLAAVLFEELAIFYLKRSLPQTTVHVEHAGSSDDYAKCIVVTGILSKELYSQYDETFWKHACRLKNFTAAVQRCCQMKDSAKTLVSDCFLEFYSEFMMGYRVTPAVIKFMFTGLINSSVTSPQSLMQACQVSSQQAMYNSVPLVTNTAFTLLRQQIFFNHVEDFIRRYGILTLGTLSPFGRLFVPTYSGLASSTVALEDAEVIARAAQTLQMNSVSIQSSSLTTLDSLGRSRTSSTAEDSSSVSDTTAASHDSGSSSSSFSFELNRPLSETELQFIKALSSLKSTQACEVIQNRITGLYCNSNEGPLDRHNVIYSSRMADSCDWLKDGKRRGNLELANRIQSVLCILIAGYYRSFGGEGTEKQVKASLNRDDNKIIEDPMIQLIPEKLRRELERLGVSRMEVDELMPSISPDDTLAQLVAKKLISLNVSTEEYSAEVSRLKQTLTARNVLHGLAGGIKELSLPIYTIFMKSYFFKDNVFLSLTDRWSTKHSTNYRDSCGKQLKGRIITKYTHWLDTFLGCSVSINRHTTVKEPSLFNPNIRCVNLITFEDGLRELSVIQSHLKVFENEFTNLNLQFSDPNRQKLRIVESRPAESELEANRAVIVKTKLFSATEQVRLSNNPAVVMGYLLDESAISEVKPTKVDFSNLLKDRFKIMQFFPSVFTLIKMLTDESSDSEKSGLSPDLQQVARYSNHLTLLSRMIQQAKPTVTVFYMLKGNLMNTEPTVAELVSYGIKEGRFFRLSDTGVDASTYSVKYWKILHCISAIGCLPLSQADKSSLLMSFLNWRVNMDIRTSDCPLSSHEASILSEFDGQVIANILASELSSVKRDSEREGLTDLLDYLNSPTELLKKKPYLGTTCKFNTWGDSNRSGKFTYSSRSGESIGIFIAGKLHIHLSSESVALLCETERQVLSWMSKRRTEVITKEQHQLFLSLLPQSHECLQKHKDGSALSVIPDSSNPRLLKFVPLKKGLAVVKIKKQILTVKKQVVFDAESEPRLQWGHGCLSIVYDETDTQTTYHENLLKVKHLVDCSTDRKKLLPQSVFSDSKVVLSRIKFKTELLLNSLTLLHCFLKHAPSDAIMEVESKSSLLHKYLKSGGVRQRNTEVLFREKLNKVVIKDNLEQGVEEEIEFCNNLTKTVSENPLPLSCWSEVQNYIEDIGFNNVLVNIDRNTVKSELLWKFTLDTNVSTTSTIKDVRTLVSYVSTETIPKFLLAFLLYEEVLMNLINQCKAVKELINSTGLSDLELESLLTLCAFYFQSECSKRDGPRCSFAALLSLIHEDWQRIGKNILVRANNELGDVSLKVNIVLVPLKDMSKPKSERVVMARRSLNHALSLMFLDEMSLPELKSLSVNCKMGNFEGQECFEFTILKDNSARLDYNKLIDHCVDMEKKREAVRAVEDLILMLTGRAVKPSAVTQFVHGDEQCQEQISLDDLMANDTVTDFPDREAEALKTGNLGFNWDSD 3AB9041361730EF5 grl-0617 GRL-0617 small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) ubiq_human UBIQ_HUMAN protein protein human Homo sapiens Human MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG isg15_bovin Ubiquitin-like protein ISG15 Interferon-stimulated gene product 17 Ubiquitin cross-reactive protein ISG15 G1P2 ISG17 UCRP protein protein bovin Bos taurus (Bovine) Bovine MGGDLTVKMLGGQEILVPLRDSMTVSELKQFIAQKINVPAFQQRLAHLDSREVLQEGVPLVLQGLRAGSTVLLVVQNCISILVRNDKGRSSPYEVQLKQTVAELKQQVCQKERVQADQFWLSFEGRPMDDEHPLEEYGLMKGCTVFMNLRLRGG 3FF8284C6438F44B l5lc70_myods MDA_GLEAN10007532 protein protein David's myotis Myotis davidii MLSNEFQVPMRDSMLLSELKQLITQKIQVPAFRQRLLVQGSNEVLQDGVPLAHQGLRSGSEVVLVVQSCDRPLSILVRNDRGNNRAYEVQLTQKVARLKEQVAERESTNVDQFWLSFQGQPLDDEKQLGEYDLTPHCTVQMNLRLRGGEEGLGGQR 31A10DDD609CA3F5 isg15_rouae ISG15_ROUAE protein protein rouae Rousettus aegyptiacus isg15_mouse Ubiquitin-like protein ISG15 Isg15 G1p2 Ucrp Interferon-induced 15 kDa protein Interferon-induced 17 kDa protein Ubiquitin cross-reactive protein protein protein mouse Mus musculus Mouse MAWDLKVKMLGGNDFLVSVTNSMTVSELKKQIAQKIGVPAFQQRLAHQTAVLQDGLTLSSLGLGPSSTVMLVVQNCSEPLSILVRNERGHSNIYEVFLTQTVDTLKKKVSQREQVHEDQFWLSFEGRPMEDKELLGEYGLKPQCTVIKHLRLRGGGGDQCA In response to IFN-tau secreted by the conceptus, may ligate to and regulate proteins involved in the release of prostaglandin F2-alpha (PGF), and thus prevent lysis of the corpus luteum and maintain the pregnancy mint Ubiquitin-like protein that is conjugated to intracellular target proteins after IFN-alpha or IFN-beta stimulation. Its enzymatic pathway is partially distinct from that of ubiquitin, differing in substrate specificity and interaction with ligating enzymes. ISG15 conjugation pathway uses a dedicated E1 enzyme, but seems to converge with the Ub conjugation pathway at the level of a specific E2 enzyme. Targets include STAT1, SERPINA3G/SPI2A, JAK1, MAPK3/ERK1, PLCG1, EIF2AK2/PKR, MX1/MxA, and RIG-1. Deconjugated by USP18/UBP43. Shows specific chemotactic activity towards neutrophils and activates them to induce release of eosinophil chemotactic factors. May serve as a trans-acting binding factor directing the association of ligated target proteins to intermediate filaments. May also be involved in autocrine, paracrine and endocrine mechanisms, as in cell-to-cell signaling, possibly partly by inducing IFN-gamma secretion by monocytes and macrophages. Seems to display antiviral activity during viral infections 9C70D9A507979171 a0a5n4dax7_camdr Cadr_000013024 protein protein camdr Camelus dromedarius Arabian camel MGGILKVKMLEGREIQVTLRDSMLLSELKQQIAQKIHVPTFQQRLAHPESQQVLKDGEPLVRQGLKPGDTVLLMVQNCEDPLSILVRNDKGRSSAYEVWLTQTVAELKRQVCQKEHAQADQFWLTFEGKPMEDQHQLGEYGLTARCTVYMNLRLRGGGAGPGGR 626354ABDB861688 rlrgg RLRGG peptide peptide polypeptide oligopeptide oligopeptide polypeptide chemical synthesis Chemical synthesis (Chemical synthesis) isg15_human Ubiquitin-like protein ISG15 ISG15 G1P2 UCRP Interferon-induced 15 kDa protein Interferon-induced 17 kDa protein Ubiquitin cross-reactive protein protein protein human Homo sapiens Human MGWDLTVKMLAGNEFQVSLSSSMSVSELKAQITQKIGVHAFQQRLAVHPSGVALQDRVPLASQGLGPGSTVLLVVDKCDEPLSILVRNNKGRSSTYEVRLTQTVAHLKQQVSGLEGVQDDLFWLTFEGKPLEDQLPLGEYGLKPLSTVFMNLRLRGGGTEPGGRS DIP protein P05161 original sequence version: 130 DIP protein P05161 original sequence version: 142 DIP protein P05161 original sequence version: 155 DIP protein P05161 original sequence version: 96 DIP protein P05161 original sequence version: 141 DIP protein P05161 original sequence version: 168 DIP protein P05161 original sequence version: 150 B6858A15AB0FFFDE a0a1s2zwt3_erieu ISG15 protein protein Western European hedgehog Erinaceus europaeus MGRTLTVKMMTGQSFEVPLTESMQLQELRQLLAQLTSVPAFQQRLILKENGKSRVLEDGPSLSSQGVQPNSMVVLVVEDCKGSLSILVRNDKGRSSLYEVRLTQKVAELKQQVSCQEHVPTDQFWLSFQGRPLEDQQLLGEYSLTSHSTVYMNLYLRGGQDHMP F14AD5DA53AC75F9 compound 6 5-N-Acetylamino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) q9gkp4_sheep ISG17 protein protein sheep Ovis aries (Sheep) Sheep MGGDLKVKMLGGEEILVPLRDSMMVSELKQFIAQKINVPAFQQRLAHLDSREVLQEGVPLVHQGLKAGSTILLMVQNCSATLNILVRNDKGRSSSYEVQLTQTVAVLKQQVCQRERVQADQFWLSFEGKPMDDEHPLGEYGLTTGCTVFMNLRLRGG B2774014826BF5FA rep-ubiq_human-1 1 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 9 enzyme target enzyme target substrate substrate neutral component neutral component purified purified C-terminus coumarin label coumarin label c-term range C-terminal range c-term range c-term range C-terminal range c-term range ecoli Escherichia coli (strain K12) cleavage cleavage reaction cleavage Table 1, figure S2 kcat/Km (uM-1 min-1) 10.3 isg15-rep-18 1 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 16 enzyme target enzyme target substrate substrate neutral component neutral component purified purified C-terminus coumarin label coumarin label c-term range C-terminal range c-term range c-term range C-terminal range c-term range ecoli Escherichia coli (strain K12) cleavage cleavage reaction cleavage Table 1, figure S2 kcat/Km (uM-1 min-1) 10.3 rep-rlrgg-1 1 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 15 enzyme target enzyme target substrate substrate neutral component neutral component purified purified C-terminus coumarin label coumarin label c-term range C-terminal range c-term range c-term range C-terminal range c-term range benzyloxycarbonyl modarg modified L-arginine residue ModArg n-term range n-terminal range n-term range n-term range n-terminal range n-term range chemical synthesis Chemical synthesis (Chemical synthesis) cleavage cleavage reaction cleavage Table 1 kcat/Km (uM-1 min-1) 0.0051 rep-ubiq_human-2 2 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 9 enzyme target enzyme target substrate substrate neutral component neutral component purified purified Lys48 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain Gly76 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) deubiquitination deubiquitination reaction deubiquitination Figure 3 Text states:- "No cleavage of any di-Ub moiety by SARS-CoV-2 PLpro was detected after 60 min (Figure S2)". I think they mean figure S3A - not S2. isg15-rep-19 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 16 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -human Moderate enzymatic activity -"pale green" result isg15-rep-20 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 10 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -cow Moderate enzymatic activity -"pale green" result isg15-rep-21 3 13 enzyme target enzyme target substrate substrate neutral component neutral component purified purified 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) cleavage cleavage reaction cleavage Figure 4 -mouse Moderate enzymatic activity -"pale green" result isg15-rep-22 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 5 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -pig Moderate enzymatic activity -"pale green" result b2lug8_pig-rep-1 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 14 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -camel Moderate enzymatic activity -"pale green" result isg17-rep-1 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 19 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -sheep High enzymatic activity -"dark green" result The stated accession number is for sheep ISG17 (AF152103.1), rather than ISG15: the sequence of the AF152103.1 (Uniprot Q9GKP4) protein has 100% homology to Sheep ISG15- Uniprot A0A6P9FNA5, and 99.4% with the longer protein W5PBE1. l5lc70_myods-rep-1 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 11 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -vesper bat High enzymatic activity -"dark green" result isg15_rouae-rep-1 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 12 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -Egyptian fruit bat Low enzymatic activity -"orange" result isg15-rep-23 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 17 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -Hedgehog Low enzymatic activity -"orange" result r9qb93_tupbe-rep-1 3 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 4 enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage Figure 4 -Northern tree Shrew Low enzymatic activity -"orange" result rep-rlrgg-2 1 8 inhibitor inhibitor neutral component neutral component chemical synthesis Chemical synthesis (Chemical synthesis) 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 15 enzyme target enzyme target substrate substrate neutral component neutral component purified purified C-terminus coumarin label coumarin label c-term range C-terminal range c-term range c-term range C-terminal range c-term range benzyloxycarbonyl modarg modified L-arginine residue ModArg n-term range n-terminal range n-term range n-term range n-terminal range n-term range chemical synthesis Chemical synthesis (Chemical synthesis) cleavage cleavage reaction cleavage Figure 5 grl_0617-rep-3 1 18 inhibitor inhibitor neutral component neutral component chemical synthesis Chemical synthesis (Chemical synthesis) 6 enzyme enzyme neutral component neutral component purified purified catalytic domain sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 15 enzyme target enzyme target substrate substrate neutral component neutral component purified purified C-terminus coumarin label coumarin label c-term range C-terminal range c-term range c-term range C-terminal range c-term range benzyloxycarbonyl modarg modified L-arginine residue ModArg n-term range n-terminal range n-term range n-term range n-terminal range n-term range chemical synthesis Chemical synthesis (Chemical synthesis) cleavage cleavage reaction cleavage Figure 5 q6tfz7_9viru-ubiq_human-1 2 9 enzyme target enzyme target substrate substrate neutral component neutral component purified purified Lys63 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain Gly76 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain Lys48 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain Lys11 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain Lys6 cross linker cross linker crosslinker crosslinker certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) 7 enzyme enzyme neutral component neutral component purified purified Ovarian Tumour Domain (OTU) sufficient to bind sufficient binding region sufficient to bind certain certain sequence position certain certain certain sequence position certain ecoli Escherichia coli (strain K12) deubiquitination deubiquitination reaction deubiquitination Supp. Figure 3B positive control I have not added any "links" for Features as they give misleading results on the public web site;how I have entered here will not. If I add as two ubiquitin molecules (which is what was used), that will give a strange result when represented as binaries - so probably safer to leave as it is here, even if not accurate.